Reviewed 19 May 2026

Example research study

GLP-1 Receptor Agonists for Addiction 

Mechanistic and Clinical Evidence for Semaglutide

Semaglutide and related GLP-1 receptor agonists dampen mesolimbic dopamine surges, enhance inhibitory GABAergic tone in the central amygdala, and reduce craving across alcohol, cocaine, nicotine, and cannabis use disorders. A Phase 2 trial reported medium-to-large effect sizes for reduced alcohol self-administration; real-world data from over 80,000 patients link semaglutide to a 50–56% lower risk of alcohol use disorder.

TL;DR GLP-1 receptors sit on GABAergic neurons in the ventral tegmental area and central amygdala — the brain's core reward circuitry. Activating them with semaglutide suppresses drug-induced dopamine spikes without flattening baseline hedonic tone. A JAMA Psychiatry Phase 2 RCT (PMID: 39937469) found semaglutide reduced alcohol craving with effect sizes exceeding those of naltrexone. Nationwide registry studies in Sweden (n = 227,866; PMID: 39535805) and the US (n = 83,825; PMID: 38806481) show 36–56% lower risk of AUD hospitalisation and incident diagnosis. Evidence for cocaine and opioid indications is earlier-stage but mechanistically grounded. Semaglutide is not yet approved for any substance use disorder; Phase 3 trials are underway.

Neurobiological Basis — GLP-1 Receptors in Addiction-Relevant Brain Circuits

The therapeutic rationale for repurposing GLP-1 receptor agonists (GLP-1RAs) in substance use disorders begins with receptor distribution. GLP-1 receptors are expressed in the ventral tegmental area (VTA), nucleus accumbens (NAc), prefrontal cortex (PFC), and central amygdala (CeA) — the principal nodes of the mesocorticolimbic reward circuit (PMID: 40843757, PMID: 40508146).

Endogenous GLP-1-producing neurons in the nucleus tractus solitarius (NTS) project directly to the VTA and NAc (PMID: 22128031). This circuit is not merely anatomical: chemogenetic activation of NTS→VTA GLP-1 projections is sufficient to attenuate cocaine seeking in rats (PMID: 40009667). Single-nuclei transcriptomics and FISH confirmed that GLP-1Rs in the VTA are expressed primarily on GABAergic interneurons, not dopamine neurons themselves (PMID: 40009667).

The downstream consequence: GLP-1R activation increases VTA GABA neuron firing, which in turn suppresses phasic dopamine release in the NAc during drug exposure — without blunting tonic dopaminergic baseline (PMID: 40843757). Peripheral GLP-1 from the gut also reaches these circuits via vagal afferents, integrating metabolic state with motivational drive (PMID: 40843757).

Semaglutide Modulates Central Amygdala GABAergic Transmission — But Dependence Changes the Response

Electrophysiology from the Leggio lab (PMID: 37192005) revealed a critical state-dependent effect. In alcohol-naive rats, acute semaglutide application consistently increased the frequency of spontaneous inhibitory postsynaptic currents (sIPSCs) in CeA neurons — meaning more presynaptic GABA release, stronger inhibitory brake on reward-seeking.

In alcohol-dependent rats, this uniform facilitation disappears. Chronic intermittent vapour exposure induces neuroadaptations that make the semaglutide response bidirectional: some CeA neurons show increased GABA release, others show decreased. The net population average is no change. The drug appears to "normalise" a dysregulated circuit rather than simply augmenting it as in the naive state (PMID: 37192005).

Semaglutide similarly increased inhibitory tone in the infralimbic cortex (ILC) of naive rats, suggesting coordinated multi-region modulation of central inhibitory control (PMID: 37192005).

Clinical Evidence in Alcohol Use Disorder — Phase 2 Trial and Registry Data

The strongest clinical dataset comes from a Phase 2, double-blind, randomised trial published in JAMA Psychiatry (PMID: 39937469). Forty-eight adults with AUD received once-weekly subcutaneous semaglutide (titrated to 0.5 mg) or placebo for 9 weeks. Semaglutide reduced laboratory alcohol self-administration with medium-to-large effect sizes: β = −0.48 for grams consumed, β = −0.46 for peak breath alcohol concentration. Weekly craving scores (Penn Alcohol Craving Scale) fell significantly (β = −0.39, medium effect).

Real-world evidence reinforces the signal. A retrospective cohort study of 83,825 patients with obesity found semaglutide associated with 50–56% lower risk for both incident and recurrent AUD over 12 months versus non-GLP-1RA medications (PMID: 38806481). A Swedish nationwide within-individual study of 227,866 individuals with AUD reported that semaglutide use carried the lowest hospitalisation risk (adjusted hazard ratio 0.64; 95% CI 0.50–0.83), outperforming naltrexone (aHR 0.86) and liraglutide (aHR 0.72) (PMID: 39535805).

GLP-1 agonists vs. naltrexone — clinical benchmarks in AUD

Metric	Semaglutide	Naltrexone
Effect size — craving reduction	Medium (β = −0.39; PMID: 39937469)	Small (d ≈ 0.20; PMID: 35133639)
Effect size — heavy drinking days	Large range (PMID: 39937469)	Small (PMID: 35133639)
AUD hospitalisation aHR (Sweden)	0.64 (95% CI 0.50–0.83)	0.86 (PMID: 39535805)
Incident AUD risk vs. comparator	HR 0.44 (95% CI 0.32–0.61; PMID: 38806481)	Reference comparator
Primary mechanism	GLP-1R → VTA GABA → dopamine suppression	μ-opioid receptor antagonism
Regulatory status for AUD	Not approved; Phase 2 complete	FDA-approved

BMI as a Predictor of GLP-1RA Efficacy in Alcohol Craving Reduction

The exenatide RCT (PMID: 36066977) revealed a sharp phenotype split: exenatide significantly reduced heavy drinking days only in patients with BMI above 30 kg/m². Lean participants (BMI below 25) actually showed an increase in heavy drinking — possibly linked to GLP-1RA-induced hypoglycaemia increasing craving in the absence of metabolic dysregulation.

Semaglutide appears to have a broader therapeutic window. The JAMA Psychiatry trial enrolled participants with 98% having BMI ≥ 25 kg/m², and exploratory subgroup comparisons did not replicate the rigid BMI-dependence seen with exenatide (PMID: 39937469). Whether this reflects semaglutide's superior CNS penetrance or its pharmacokinetic profile remains under investigation (PMID: 40309769).

Semaglutide Targets 'Wanting' Over 'Liking' — Incentive Salience Without Anhedonia

A central concern with any anti-addiction pharmacotherapy is whether it flattens all pleasure or selectively reduces pathological motivation. The evidence favours selectivity for semaglutide. Clinical neuroimaging of the GLP-1RA exenatide demonstrated reduced alcohol cue reactivity in the ventral striatum — the region that translates reward-predictive cues into seeking behaviour — without diminishing responses to neutral stimuli (PMID: 36066977).

In rodent models, semaglutide reduces alcohol preference without decreasing water intake, indicating selective reduction in the reinforcing value of alcohol rather than generalised consummatory suppression (PMID: 37192005). However, not all measures align: one study found semaglutide did not reduce alcohol-induced conditioned place preference (CPP) despite reducing intake, suggesting the hedonic memory of alcohol may persist even as the motivational drive to seek it weakens (PMID: 40508146).

The dopaminergic mechanism supports this distinction. GLP-1R activation dampens phasic dopamine — the signal encoding incentive salience and "wanting" — while preserving tonic dopamine, which underpins baseline mood and hedonic capacity (PMID: 40843757, PMID: 40508146).

Beyond Alcohol — Evidence for Cocaine, Nicotine, Cannabis, and Opioid Use Disorders

The GLP-1 addiction hypothesis extends well beyond alcohol. The strongest non-AUD evidence comes from cannabis and nicotine; cocaine and opioid data are more preliminary.

Cannabis use disorder: A retrospective cohort study of 85,223 patients with obesity found semaglutide associated with 44% lower risk of incident CUD (HR 0.56; 95% CI 0.42–0.75) and 38% lower risk of recurrent CUD (HR 0.62; 95% CI 0.46–0.84) compared with non-GLP-1RA anti-obesity medications (PMID: 38486046).

Nicotine: A secondary analysis of the semaglutide AUD trial found a significant treatment-by-time interaction predicting greater reductions in cigarettes smoked per day among participants who also smoked (PMID: 39937469).

Cocaine: Preclinical evidence is robust — chemogenetic NTS→VTA GLP-1 circuit activation attenuates cocaine seeking (PMID: 40009667). However, a single low-dose exenatide challenge failed to reduce craving in a small clinical study, suggesting repeated dosing may be necessary (PMID: 40843757).

Opioids: Preliminary clinical findings reported a 40% reduction in opioid craving with liraglutide in individuals with OUD, but well-powered RCTs are absent (PMID: 40843757).

GLP-1RA evidence by substance use disorder — current status

Substance	Strongest Evidence	Maturity
Alcohol	Phase 2 RCT + two large registry studies	Phase 3 trials underway
Cannabis	Retrospective cohort (n = 85,223)	Observational only
Nicotine	Secondary analysis of AUD trial	Preliminary signal
Cocaine	Preclinical circuit dissection; single-dose clinical null	Preclinical lead
Opioids	Preliminary liraglutide craving reduction	Earliest stage

The Lateral Septum — A Newly Identified GLP-1R Node in Alcohol Reward Processing

Recent work by Edvardsson et al. (PMID: 40245495) identifies the lateral septum (LS) as an additional GLP-1R-rich region with direct relevance to alcohol reward. Intra-LS infusion of the GLP-1R agonist exendin-4 dose-dependently reduced alcohol intake without affecting food or water consumption. Conversely, blocking LS GLP-1Rs increased alcohol intake.

LS GLP-1R activation attenuated alcohol-induced locomotor stimulation, conditioned place preference, and accumbal dopamine release — three distinct facets of reward processing. Ex vivo electrophysiology indicated that GLP-1R activation depresses LS neurotransmission via a GABA-receptor-dependent mechanism, paralleling the VTA and CeA findings.

Notably, LS GLP-1R expression correlated with alcohol intake in male but not female rats, pointing to sex-specific long-term adaptations that may inform patient selection in future trials.

How BioSkepsis Synthesised This Evidence — Citation-Verified Literature Analysis

The BioSkepsis research thread underlying this post ran a multi-step, citation-grounded synthesis across 14 PubMed-indexed sources. Every claim was tagged with a directness label (Direct, Indirect, or Derived) and a confidence tier (High, Medium, or Low). Citations that failed any of three independent verification checks — abstract match, conclusion match, and specificity match — were flagged as unverified and excluded from the primary synthesis.

This matters because the GLP-1-addiction field is moving fast, and several high-profile claims have circulated with inaccurate citation support. For example, one source cited a "9% reduction in cocaine craving" when the actual paper reported 58.9%; another cited an "8% abstinence rate" when the paper reported 46.3%. BioSkepsis caught both.

Frequently asked questions

Is semaglutide FDA-approved for treating alcohol use disorder?

No. Semaglutide is approved for type 2 diabetes and obesity. Its use in alcohol use disorder is supported by Phase 2 trial data (PMID: 39937469) and real-world registry studies (PMID: 38806481, PMID: 39535805), but Phase 3 trials are still needed before regulatory approval for AUD.

Which brain regions express GLP-1 receptors relevant to addiction?

GLP-1 receptors are expressed in the ventral tegmental area (VTA), nucleus accumbens (NAc), prefrontal cortex (PFC), central amygdala (CeA), and lateral septum — all key nodes in the mesolimbic reward circuit that drives substance-seeking behaviour (PMID: 40843757, PMID: 40508146, PMID: 40245495).

How does semaglutide reduce alcohol craving compared to naltrexone?

In a Phase 2 trial, semaglutide produced medium-to-large effect sizes for reducing craving and heavy drinking, whereas naltrexone typically shows small effect sizes (Cohen's d ≈ 0.20). A Swedish registry study found semaglutide's hazard ratio for AUD hospitalisation (0.64) was lower than naltrexone's (0.86) (PMID: 39937469, PMID: 39535805).

Does body weight affect semaglutide's efficacy in addiction?

Earlier GLP-1 agonists like exenatide only reduced heavy drinking in patients with BMI above 30 kg/m² (PMID: 36066977). Recent semaglutide data suggest consistent anti-craving effects across the overweight-to-obese spectrum, though safety in lean individuals (BMI below 25) remains uncertain (PMID: 39937469).

What evidence exists for GLP-1 agonists in cocaine or opioid addiction?

Preclinical work shows that activating endogenous GLP-1 circuits in the VTA attenuates cocaine seeking in rats (PMID: 40009667). A single low-dose exenatide challenge did not reduce cocaine craving in humans. Preliminary data report a 40% reduction in opioid craving with liraglutide, but larger trials are needed (PMID: 40843757).

Does semaglutide cause general anhedonia or suppress natural reward?

Evidence suggests semaglutide selectively targets pathological "wanting" (incentive salience) while preserving hedonic responses to natural rewards. Rodent studies show reduced alcohol preference without decreased water intake (PMID: 37192005). However, semaglutide may not reduce the hedonic memory of alcohol (conditioned place preference), suggesting "liking" is partially preserved (PMID: 40508146).

How did BioSkepsis synthesise this evidence?

BioSkepsis ran a citation-verified literature synthesis across 14 PubMed-indexed sources, grading each claim by directness and confidence. Every citation was cross-checked against the original abstract, and unverified citations were flagged transparently — including two citations where the claimed effect sizes diverged substantially from the source paper's actual findings.

Run Your Own GLP-1 and Addiction Literature Synthesis on BioSkepsis

BioSkepsis verifies every citation against PubMed, grades evidence by directness and confidence, and flags discrepancies automatically — so you can trust the synthesis before it reaches your manuscript or clinical review.

Start free

Sources & further reading

1. Amorim Moreira Alves G, et al. Mechanisms of GLP-1 in Modulating Craving and Addiction. Med Sci (Basel). 2025;13(3):136. PMID: 40843757
2. Marquez-Meneses JD, et al. GLP-1 Analogues in the Neurobiology of Addiction. Int J Mol Sci. 2025;26(11):5338. PMID: 40508146
3. Merkel R, et al. An endogenous GLP-1 circuit engages VTA GABA neurons to attenuate cocaine seeking. Sci Adv. 2025;11(9):eadr5051. PMID: 40009667
4. Chuong V, et al. The GLP-1 analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight. 2023;8(12). PMID: 37192005
5. Alhadeff AL, et al. GLP-1 neurons in the NTS project to VTA and NAc. Endocrinology. 2012;153(2):647–58. PMID: 22128031
6. Hendershot CS, et al. Once-weekly semaglutide in adults with AUD: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395–405. PMID: 39937469
7. Wang W, et al. Semaglutide and incidence/recurrence of AUD in real-world population. Nat Commun. 2024;15(1):4548. PMID: 38806481
8. Klausen MK, et al. Exenatide once weekly for AUD: a randomized, placebo-controlled clinical trial. JCI Insight. 2022;7(19). PMID: 36066977
9. Wang W, et al. Semaglutide and reduced incidence/relapse of cannabis use disorder. Mol Psychiatry. 2024;29(8):2587–2598. PMID: 38486046
10. Lähteenvuo M, et al. Repurposing semaglutide and liraglutide for AUD. JAMA Psychiatry. 2025;82(1):94–98. PMID: 39535805
11. Burnette EM, et al. Novel agents for AUD pharmacological treatment. Drugs. 2022;82(3):251–274. PMID: 35133639
12. Petrie GN, Mayo LM. GLP-1 receptor agonists for AUD treatment. J Clin Invest. 2025;135(9). PMID: 40309769
13. Klausen MK, et al. Effects of GLP-1 receptor agonists in AUD. Basic Clin Pharmacol Toxicol. 2025;136(3):e70004. PMID: 39891507
14. Edvardsson CE, et al. An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake. EBioMedicine. 2025;115:105684. PMID: 40245495